We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
- Authors
Liu, Chen‐hua; Liu, Chun‐jen; Su, Tung‐hung; Yang, Hung‐chih; Hong, Chun‐ming; Tseng, Tai‐chung; Chen, Pei‐jer; Chen, Ding‐shinn; Kao, Jia‐horng
- Abstract
Abstract: Background and Aim: The real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV‐1b) patients. The study aimed to evaluate the antiviral responses of PrOD‐based regimens for HCV‐1b patients in Taiwan. Methods: The study performed a retrospective analysis of 103 HCV‐1b patients receiving PrOD with or without ribavirin (RBV) for 12 weeks. Data were analyzed to assess the on‐treatment and off‐therapy HCV viral load and on‐treatment adverse events. The pre‐specified characteristics related to sustained virologic response 12 weeks off therapy (SVR12) were compared. Results: At treatment week 4, 100 of 102 patients (98.0%) had serum HCV RNA level < 25 IU/mL. The SVR12 was achieved in 101 of 103 patients (98.1%, [95% confidence interval: 93.2–99.5%]). All except one (99.0%) patients tolerated treatment well without treatment interruption. One cirrhotic patient discontinued treatment at week 1 due to hepatic decompensation. Twenty‐four patients (23.3%) had ≥ grade 2 elevation in total bilirubin levels, and 21 of them (87.5%) had indirect type hyperbilirubinemia. The stratified SVR12 rates were comparable in terms of sex, age, body mass index, prior treatment experience, hepatitis B virus surface antigen status, RBV usage, baseline and week 2 viral load, renal function, and hepatic fibrosis stage. Conclusions: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without RBV are efficacious and generally well tolerated for treatment of HCV‐1b patients in Taiwan.
- Subjects
DRUG efficacy; RITONAVIR; CHRONIC hepatitis C; ANTIVIRAL agents; VIRAL load; THERAPEUTICS
- Publication
Journal of Gastroenterology & Hepatology, 2018, Vol 33, Issue 3, p710
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/jgh.13912